Omega-3 Fatty Acids Supplementation in Children to Prevent Asthma: Is It Worthy?—A Systematic Review and Meta-Analysis

Table 2

Details of included studies.

Serial number	Author	Year	Place	Sample size	Age/sex	Intervention and dose	Comparator and dose	Follow-up (years)	Outcomes studied	Conflict of interests	Funding
1	Mihrshahi et al. [29]	2003	Australia	616/554	6–18 months/ both	o-3–rich tuna fish oil (500 mg) from the age of 6 months.	Sunola oil	1	Number of episodes of wheeze or cough lasting for >1 week not associated with colds	None	Institute of Health
2	Marks et al. [30]	2006	Australia	616/516	6 months to 5 years	Oil capsules with 500 mg tuna fish oil (37% o-3 PUFA + 6% o-6)	Oil capsules with 0.3% o-3 + 7% o-6 PUFA	5	Episodes of wheeze, asthma	None	Institute of Health
3	Birch et al. [31]	2010	USA	147/89	<5 days–12 months/ both	DHA and ARA as 0.32%–0.36% and 0.64%–0.72% of total FA	Enfamil with iron	3	Diagnoses of wheezing, asthma	None	National Institute of Health USA
4	D’Vaz et al. [32]	2012	Australia	420/323	0–6 months/ both	650 mg fish oil capsules (280 mg DHA + 110 mg EPA) daily	650 mg olive oil (66.6% n-9 oleic acid)	0.5	Physician diagnosed IgE-mediated asthma episodes	None	National Health and Medical Research Council (NHMRC)
5	Ng et al. [33]	2010	Australia	616/450	Birth to 5 years/ both	Oil capsules, 500 mg tuna fish oil (37% o-3 PUFA + 6% o-6 PUFA)	500 mg Sunola oil capsules (0.3% o-3 + 7% o-6 PUFA)	8	ARR of wheezing episodes, asthma	None	Institute of Health

DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; ARA: arachidonic acid; PUFA: polyunsaturated fatty acid; ARR: absolute risk reduction; o-3: omega-3; o-6: omega-6; FA: fatty acids; sample size: number of participants who were given supplements/number of participants who completed the trial.